Medical Devices · Nasdaq: GEHC
GE HealthCare earnings: results, call transcripts & KPI history
2 quarters · fiscal year ends December · next results expected around 3 Feb 2027
Latest: Q3 2026
GE HealthCare agreed to buy SOFIE Biosciences, adding final-mile PET radiopharmaceutical supply to its drug-plus-imaging strategy as new imaging platforms clear regulatory milestones.
GE HealthCare's growth came from Advanced Imaging Solutions and Pharmaceutical Diagnostics, with orders still healthy and a backlog of $23.7 billion. It won CE marking for the Photonova Spectra photon-counting CT, has StarGuide GX SPECT/CT pending with the FDA, and launched new ultrasound products. Contrast media and radiopharmaceuticals drove Pharmaceutical Diagnostics. Patient Care Solutions recovered as supply and fulfillment improved under the company's Heartbeat operating system.
Quarters
KPI history
Fourth quarter worked out from the annual figure.
Data
| Q4 2024 | $5.3B * |
| Q1 2025 | $4.8B |
| Q2 2025 | $5.0B |
| Q3 2025 | $5.1B |
| Q4 2025 | $5.7B * |
| Q1 2026 | $5.1B |
| Q2 2026 | $5.3B |
| Q3 2026 | $5.5B |
Data
| Q1 2025 | $1.23 |
| Q2 2025 | $1.06 |
| Q3 2025 | $0.98 |
| Q1 2026 | $0.85 |
| Q2 2026 | $1.24 |
| Q3 2026 | $1.36 |
Fourth-quarter EPS appears once the press release is read; filings report it only for the full year.
Data
| Q4 2024 | 15.1% |
| Q1 2025 | 13.2% |
| Q2 2025 | 13.1% |
| Q3 2025 | 12.7% |
| Q4 2025 | 14.5% |
| Q1 2026 | 10.0% |
| Q2 2026 | 14.0% |
| Q3 2026 | 14.6% |
Data
| Q1 2025 | $98.0M |
| Q2 2025 | $8.0M |
| Q3 2025 | $483.0M |
| Q1 2026 | $112.0M |
| Q2 2026 | $68.0M |
| Q3 2026 | $793.0M |
Operating cash flow minus capital expenditure, from cash flow statements.
| Q4 2024 | Q1 2025 | Q2 2025 | Q3 2025 | Q4 2025 | Q1 2026 | Q2 2026 | Q3 2026 | |
|---|---|---|---|---|---|---|---|---|
| Revenue | $5.3Bd | $4.8B | $5.0B | $5.1B | $5.7Bd | $5.1B | $5.3B | $5.5B |
| Gross margin | 42.8% | 42.1% | 39.6% | 38.7% | 39.7% | 38.5% | 41.2% | 40.3% |
| Operating income | $801.0Md | $629.0M | $654.0M | $653.0M | $827.0Md | $515.0M | $739.0M | $805.0M |
| Operating margin | 15.1% | 13.2% | 13.1% | 12.7% | 14.5% | 10.0% | 14.0% | 14.6% |
| Net income | $721.0Md | $564.0M | $486.0M | $446.0M | $589.0Md | $389.0M | $561.0M | $615.0M |
| Diluted EPS | — | $1.23 | $1.06 | $0.98 | — | $0.85 | $1.24 | $1.36 |
| Operating cash flow | — | $250.0M | $94.0Md | $593.0Md | — | $290.0M | $168.0Md | $907.0Md |
| Capital expenditure | $102.0Md | $152.0M | $86.0Md | $110.0Md | $134.0Md | $178.0M | $100.0Md | $114.0Md |
| Free cash flow | — | $98.0M | $8.0M | $483.0M | — | $112.0M | $68.0M | $793.0M |
| R&D expense | $344.0Md | $344.0M | $302.0M | $292.0M | $323.0Md | $345.0M | $323.0M | $320.0M |
From XBRL data in 10-Q and 10-K filings. d derived: a fourth quarter is the full year minus the first nine months, and cash flows are year-to-date figures differenced.
10-K and 10-Q filings
- 28 Oct 202610-Q for the period ended 30 Sep 2026SEC ↗
- 29 Jul 202610-Q for the period ended 30 Jun 2026SEC ↗
- 29 Apr 202610-Q for the period ended 31 Mar 2026SEC ↗
- 4 Feb 202610-K for the period ended 31 Dec 2025SEC ↗
- 29 Oct 202510-Q for the period ended 30 Sep 2025SEC ↗
- 30 Jul 202510-Q for the period ended 30 Jun 2025SEC ↗
- 30 Apr 202510-Q for the period ended 31 Mar 2025SEC ↗
- 13 Feb 202510-K for the period ended 31 Dec 2024SEC ↗